Stryker (SYK) Q2 2024 earnings summary

Executive summary

• Achieved 9% organic sales growth in Q2 2024, with balanced U.S. and international performance and high single-digit growth in both MedSurg & Neurotechnology and Orthopaedics & Spine.

• Adjusted EPS grew 10.6% to $2.81, with strong sales, margin expansion, and robust demand for capital products.

• Completed acquisitions of Artelon, MOLLI Surgical, and SERF SAS, enhancing product portfolios in soft tissue fixation, breast lesion localization, and joint replacement.

• Net earnings reached $825M ($2.14 per diluted share) in Q2, with reported EPS up 10.9%.

• Record Mako installations for three consecutive quarters, with over 1 million robotic total knee procedures performed to date.

Financial highlights

• Q2 net sales: $5,422M (up from $4,996M in Q2 2023); organic sales growth of 9% and net sales up 8.5%.

• Adjusted EPS of $2.81, up 10.6% year-over-year; adjusted gross margin of 64.2%, up 30 bps year-over-year.

• Adjusted operating margin of 24.6%, up 30 bps year-over-year; reported operating margin 19.4%.

• Ended Q2 with $2B in cash/marketable securities and $12.2B in total debt; repaid $600M of debt in May.

• Year-to-date cash from operations: $837M; net cash used in investing: $525M.

Outlook and guidance

• Raised 2024 full-year organic sales growth guidance to 9%-10% and adjusted EPS to $11.90-$12.10, with a $0.10-$0.15 negative FX impact.

• Expect continued strong procedural demand and capital product backlog, with new product launches (Pangea, LIFEPAK 35, Mako Spine, Copilot, Mako Shoulder) driving growth in H2 2024 and 2025.

• Anticipate 0.5% favorable pricing impact for 2024.

• Management expects continued inflationary pressures, higher interest rates, and supply chain challenges.